Repare Therapeutics Inc. (“Repare” or the “Company”) announces the completion of the previously announced acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, by way of a statutory plan of arrangement (the “Transaction” or the “Arrangement”). Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
Read the full article: Repare Announces Completion of Acquisition by XenoTherapeutics, Inc. //
Source: https://www.businesswire.com/news/home/20260128195211/en/Repare-Announces-Completion-of-Acquisition-by-XenoTherapeutics-Inc.